Emory University researchers have made a significant advancements in the pursuit of an HIV cure. One of the teams, led by Dr. Rafick Sekaly and Dr. Mirko Paiardini, demonstrated unprecedented control of simian immunodeficiency virus (SIV) replication and decay of viral reservoirs in nonhuman primates.

Key Findings:

The study, which was published in Nature Immunology, combined a stringent model of SIV infection with interruption of antiretroviral therapy (ART) and targeted immune intervention.

Researchers identified mechanisms of action for PD1 and IL-10, molecules known to regulate HIV persistence and immune dysfunction.

Nine of ten monkeys that received combination treatment showed durable control of viral rebound lasting six months after stopping ART.

Implications for HIV Treatment:

This research represents a major step forward in developing a functional cure for HIV, potentially improving the lives of 39 million people living with the disease worldwide. The study’s success stems from more than 15 years of work on PD1 and IL-10, which could lead to improved approaches for restoring deficient immune systems and controlling chronic infections.

Collaborative Effort:

The study highlights the power of collaboration between academia and industry. Merck, as an industry partner, developed reagents specifically designed to target PD1 and IL10 molecules in nonhuman primate models.

Up Next:

The research team is further investigating innate immune, metabolic and epigenetic pathways associated with controlling the virus after ending treatment. Their goal is to develop interventions that can induce an immune response capable of long-term control of HIV and SIV without ART.

This breakthrough brings us one step closer to a potential HIV cure, offering hope to millions affected by the disease worldwide.